Efficacy of hepatic arterial infusion chemotherapy and its combination strategies for advanced hepatocellular carcinoma: A network meta-analysis

Table 1 League table for clinical outcomes

League table
OS
HAIC + Lenv + A		0.42 (0.12; 1.44)
0.58 (0.09; 3.84)	HAIC + A					0.38 (0.12; 1.17)
0.42 (0.12; 1.44)	0.73 (0.17; 3.08)	HAIC + Lenv			0.52 (0.21; 1.28)
0.36 (0.05; 2.31)	0.61 (0.13; 2.93)	0.84 (0.20; 3.46)	HAIC + PD-1		0.62 (0.21; 1.84)
0.24 (0.05; 1.17)	0.41 (0.12; 1.39)	0.56 (0.20; 1.56)	0.66 (0.20; 2.20)	HAIC + Sora	0.43 (0.12; 1.47)	0.58 (0.36; 0.94)
0.24 (0.04; 1.63)	0.42 (0.08; 2.09)	0.58 (0.13; 2.47)	0.68 (0.14; 3.32)	1.03 (0.31; 3.43)	HAIC + RT		0.50 (0.16; 1.52)
0.22 (0.05; 1.01)	0.38 (0.12; 1.17)	0.52 (0.21; 1.28)	0.62 (0.21; 1.84)	0.94 (0.57; 1.55)	0.91 (0.29; 2.85)	HAIC	0.53 (0.40; 0.70)		0.50 (0.33; 0.75)	0.32 (0.11; 0.95)
0.12 (0.03; 0.57)	0.21 (0.07; 0.67)	0.29 (0.11; 0.74)	0.34 (0.11; 1.05)	0.52 (0.33; 0.81)	0.50 (0.16; 1.52)	0.55 (0.42; 0.72)	Sora
0.11 (0.01; 0.84)	0.18 (0.03; 1.10)	0.25 (0.05; 1.33)	0.30 (0.05; 1.76)	0.45 (0.10; 2.00)	0.44 (0.07; 2.66)	0.48 (0.12; 1.95)	0.88 (0.21; 3.63)	HAIC + TACE + S-1	1.00 (0.35; 2.86)
0.11 (0.02; 0.63)	0.18 (0.04; 0.78)	0.25 (0.07; 0.91)	0.30 (0.07; 1.24)	0.45 (0.16; 1.29)	0.44 (0.10; 1.90)	0.48 (0.19; 1.21)	0.88 (0.34; 2.28)	1.00 (0.35; 2.86)	HAIC + TACE	1.03 (0.45; 2.34)
0.11 (0.02; 0.53)	0.19 (0.06; 0.63)	0.26 (0.10; 0.70)	0.31 (0.10; 0.99)	0.47 (0.24; 0.90)	0.45 (0.13; 1.52)	0.50 (0.33; 0.75)	0.90 (0.55; 1.47)	1.03 (0.27; 3.91)	1.03 (0.45; 2.34)	TACE
0.07 (0.01; 0.46)	0.12 (0.03; 0.58)	0.17 (0.04; 0.68)	0.20 (0.04; 0.92)	0.30 (0.09; 0.99)	0.29 (0.06; 1.40)	0.32 (0.11; 0.95)	0.58 (0.19; 1.77)	0.66 (0.11; 3.87)	0.66 (0.16; 2.73)	0.64 (0.20; 2.04)	BSC
PFS
HAIC + A						0.49 (0.17; 1.39)
0.96 (0.17; 5.46)	HAIC + Lenv + A						0.46 (0.16; 1.36)
0.85 (0.16; 4.50)	0.89 (0.13; 5.94)	HAIC + TACE + S-1	0.90 (0.31; 2.59)
0.77 (0.21; 2.77)	0.80 (0.17; 3.87)	0.90 (0.31; 2.59)	HAIC + TACE					0.39 (0.22; 0.70)
0.75 (0.17; 3.29)	0.78 (0.14; 4.44)	0.88 (0.17; 4.61)	0.97 (0.27; 3.50)	HAIC + PD-1	0.65 (0.23; 1.85)
0.53 (0.10; 2.70)	0.55 (0.09; 3.58)	0.62 (0.10; 3.73)	0.69 (0.16; 2.94)	0.71 (0.14; 3.61)	HAIC + RT					0.47 (0.14; 1.52)
0.49 (0.17; 1.39)	0.51 (0.13; 2.04)	0.57 (0.16; 2.07)	0.63 (0.30; 1.32)	0.65 (0.23; 1.85)	0.92 (0.26; 3.21)	HAIC	0.91 (0.38; 2.16)	0.62 (0.39; 0.98)	0.51 (0.33; 0.78)
0.44 (0.11; 1.72)	0.46 (0.16; 1.36)	0.52 (0.11; 2.45)	0.57 (0.18; 1.80)	0.59 (0.15; 2.30)	0.84 (0.18; 3.83)	0.91 (0.38; 2.16)	HAIC + Lenv
0.39 (0.11; 1.32)	0.40 (0.09; 1.86)	0.45 (0.11; 1.91)	0.50 (0.19; 1.34)	0.52 (0.15; 1.76)	0.73 (0.20; 2.61)	0.79 (0.42; 1.51)	0.87 (0.30; 2.57)	HAIC + Sora	0.64 (0.40; 1.03)
0.30 (0.10; 0.95)	0.31 (0.07; 1.36)	0.35 (0.11; 1.18)	0.39 (0.22; 0.70)	0.40 (0.13; 1.26)	0.57 (0.15; 2.16)	0.62 (0.39; 0.98)	0.68 (0.26; 1.82)	0.78 (0.36; 1.72)	TACE
0.25 (0.08; 0.77)	0.26 (0.06; 1.10)	0.29 (0.07; 1.12)	0.32 (0.14; 0.75)	0.33 (0.11; 1.02)	0.47 (0.14; 1.52)	0.51 (0.33; 0.78)	0.56 (0.21; 1.47)	0.64 (0.40; 1.03)	0.82 (0.44; 1.53)	Sora
CR
HAIC + Sora			6.21 (0.28; 138.56)		6.77 (2.11; 21.68)
1.46 (0.02; 90.79)	HAIC + PD-1		1.82 (0.04; 92.69)
2.27 (0.22; 22.94)	1.55 (0.02; 123.86)	HAIC + TACE + S-1	1.10 (0.26; 4.62)
2.49 (0.41; 15.27)	1.70 (0.03; 106.73)	1.10 (0.26; 4.62)	HAIC + TACE				3.30 (1.20; 9.03)
2.66 (0.75; 9.46)	1.82 (0.04; 92.69)	1.17 (0.17; 8.14)	1.07 (0.29; 3.91)	HAIC	1.93 (0.09; 42.76)	2.13 (0.32; 14.10)	3.01 (1.41; 6.41)	3.08 (1.36; 6.98)
5.15 (0.18; 146.19)	3.52 (0.02; 524.16)	2.27 (0.06; 87.52)	2.07 (0.07; 59.37)	1.93 (0.09; 42.76)	BSC
5.67 (0.58; 55.24)	3.87 (0.05; 303.50)	2.50 (0.17; 37.42)	2.27 (0.23; 22.55)	2.13 (0.32; 14.10)	1.10 (0.03; 41.42)	HAIC + Lenv
7.62 (2.55; 22.77)	5.21 (0.10; 283.99)	3.36 (0.42; 26.67)	3.06 (0.69; 13.61)	2.86 (1.37; 5.98)	1.48 (0.06; 35.69)	1.35 (0.18; 10.25)	Sora
8.21 (1.82; 37.10)	5.62 (0.10; 310.71)	3.62 (0.63; 20.94)	3.30 (1.20; 9.03)	3.08 (1.36; 6.98)	1.59 (0.06; 39.20)	1.45 (0.18; 11.38)	1.08 (0.36; 3.24)	TACE
PR
HAIC + TACE + S-1		2.34 (0.86; 6.40)
1.59 (0.42; 6.00)	HAIC + Lenv			1.54 (0.92; 2.56)
1.72 (0.44; 6.65)	1.08 (0.50; 2.33)	HAIC + PD-1		1.42 (0.80; 2.51)
2.34 (0.86; 6.40)	1.48 (0.62; 3.53)	1.36 (0.55; 3.37)	HAIC + TACE		2.16 (1.14; 4.08)
2.42 (0.61; 9.51)	1.52 (0.69; 3.37)	1.41 (0.61; 3.23)	1.03 (0.41; 2.62)	HAIC + Sora	5.00 (1.19; 21.04)		4.50 (2.71; 7.48)
2.44 (0.72; 8.32)	1.54 (0.92; 2.56)	1.42 (0.80; 2.51)	1.04 (0.51; 2.11)	1.01 (0.55; 1.85)	HAIC	2.07 (1.54; 2.80)	4.62 (0.24; 89.16)	6.32 (4.08; 9.80)
5.05 (1.54; 16.61)	3.18 (1.76; 5.76)	2.94 (1.55; 5.59)	2.16 (1.14; 4.08)	2.09 (1.06; 4.12)	2.07 (1.54; 2.80)	TACE
11.28 (0.46; 277.69)	7.10 (0.35; 143.15)	6.56 (0.32; 133.57)	4.81 (0.23; 100.83)	4.67 (0.23; 95.70)	4.62 (0.24; 89.16)	2.23 (0.11; 43.69)	BSC
13.29 (3.63; 48.61)	8.37 (4.32; 16.23)	7.73 (3.81; 15.68)	5.67 (2.49; 12.89)	5.50 (3.40; 8.89)	5.45 (3.57; 8.30)	2.63 (1.57; 4.41)	1.18 (0.06; 23.41)	Sora
ORR
HAIC + TACE + S-1		1.99 (0.40; 9.99)
1.28 (0.12; 14.33)	HAIC + Lenv			1.95 (0.51; 7.44)
1.76 (0.15; 21.24)	1.37 (0.19; 10.05)	HAIC + PD-1		1.42 (0.33; 6.19)
1.96 (0.21; 18.19)	1.53 (0.29; 7.97)	1.11 (0.19; 6.47)	HAIC + Sora	8.00 (1.08; 59.18)		6.08 (2.38; 15.59)
1.99 (0.40; 9.99)	1.55 (0.26; 9.34)	1.13 (0.17; 7.53)	1.02 (0.22; 4.74)	HAIC + TACE		3.97 (1.43; 11.04)
2.50 (0.34; 18.61)	1.95 (0.51; 7.44)	1.42 (0.33; 6.19)	1.28 (0.48; 3.37)	1.26 (0.38; 4.15)	HAIC	1.93 (0.07; 56.84)	3.16 (1.71; 5.85)	8.36 (4.66 15.01)
4.84 (0.09; 246.61)	3.77 (0.10; 143.00)	2.74 (0.07; 109.59)	2.47 (0.07; 83.18)	2.43 (0.07; 87.58)	1.93 (0.07; 56.84)	BSC
7.91 (1.17; 53.36)	6.16 (1.41; 26.89)	4.48 (0.91; 22.12)	4.04 (1.28; 12.73)	3.97 (1.43; 11.04)	3.16 (1.71; 5.85)	1.63 (0.05; 50.80)	TACE
17.88 (2.22; 143.80)	13.92 (3.25; 59.60)	10.14 (2.09; 49.09)	9.13 (3.87; 21.51)	8.97 (2.39; 33.65)	7.15 (4.06; 12.58)	3.70 (0.12; 113.89)	2.26 (0.98; 5.22)	Sora
DCR
HAIC + TACE + S-1	2.04 (0.55; 7.61)
1.17 (0.15; 9.35)	HAIC + PD-1	2.52 (0.72; 8.81)
2.04 (0.55; 7.61)	1.74 (0.35; 8.65)	HAIC + TACE				3.87 (1.64; 9.11)
2.95 (0.56; 15.45)	2.52 (0.72; 8.81)	1.45 (0.53; 3.94)	HAIC	1.40 (0.45; 4.37)	0.06 (0.00; 1.40)	1.71 (0.33; 8.88)	2.67 (1.59; 4.50)	3.02 (2.08; 4.40)
4.14 (0.56; 30.84)	3.53 (0.65; 19.15)	2.03 (0.45; 9.24)	1.40 (0.45; 4.37)	HAIC + Lenv
4.38 (0.71; 26.90)	3.73 (0.87; 16.04)	2.15 (0.62; 7.49)	1.48 (0.70; 3.13)	1.06 (0.27; 4.11)	HAIC + Sora		1.68 (0.86; 3.29)
5.05 (0.49; 52.13)	4.30 (0.54; 34.07)	2.47 (0.36; 17.01)	1.71 (0.33; 8.88)	1.22 (0.16; 9.01)	1.15 (0.19; 7.03)	BSC
7.89 (1.64; 37.97)	6.73 (1.73; 26.11)	3.87 (1.64; 9.11)	2.67 (1.59; 4.50)	1.90 (0.55; 6.64)	1.80 (0.73; 4.48)	1.56 (0.28; 8.79)	TACE
8.52 (1.56; 46.49)	7.26 (1.97; 26.84)	4.18 (1.43; 12.17)	2.89 (1.99; 4.19)	2.06 (0.62; 6.80)	1.95 (1.01; 3.75)	1.69 (0.31; 9.14)	1.08 (0.57; 2.05)	Sora

HAIC: Hepatic arterial infusion chemotherapy; Sora: Sorafenib; Lenv: Lenvatinib; TACE: Transarterial chemoembolization; RT: Radiotherapy; S-1: A composite preparation of a 5-fluorouracil prodrug; A: Ablation; PD-1: Programmed death 1; BSC: Best supportive care.